MMM vs RCEL
MMM: 3M is a diversified industrial manufacturer spanning safety, healthcare, transportation, and consumer products through decades of materials science innovation and global distribution. RCEL: A therapeutic wound care company commercializing RECELL, an autologous cell harvesting device that creates patient-derived skin cell suspension for treating burns and traumatic injuries, now expanding into a multi-product acute wound care platform.
Side-by-side fundamentals
| Metric | MMM | RCEL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $170.76 | $4.94 | |
| Market cap as of 2026-07-23 | $89.9B | $157M | |
| P/E as of 2026-07-23 | 29.99 | n/a | |
| PEG as of 2026-07-23 | 3.65 | n/a | |
| Net margin as of 2026-07-23 | +11.9% | -62.7% | MMM higher |
| Gross margin as of 2026-07-23 | +39.4% | +82.1% | RCEL higher |
| Operating margin as of 2026-07-23 | +18.4% | -54.6% | MMM higher |
| ROE as of 2026-07-23 | +76.9% | -337.9% | MMM higher |
| ROA as of 2026-07-23 | +8.2% | -78.9% | MMM higher |
| Debt / equity as of 2026-07-23 | 4.18 | 9.39 | MMM lower |
| Revenue growth (YoY) as of 2026-07-23 | +2.4% | +1.0% | MMM higher |
| Revenue CAGR (3y) SEC XBRL | -1.6% | +27.7% | RCEL higher |
| Dividend yield as of 2026-07-23 | +1.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | 1 | n/a | |
| Beta as of 2026-07-23 | 1.02 | 1.84 | |
| 1-year return as of 2026-07-22 close | +12.9% | -15.0% | MMM higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.